Lurie Children’s Becomes First Treatment Center for Zevaskyn Gene Therapy in Patients with RDEB

1st US site offering Zevaskyn for RDEB opens in Chicago

Ann & Robert H. Lurie Children’s Hospital of Chicago opened the first Qualified Treatment Center (QTC) in the U.S. authorized to offer Zevaskyn (prademagene zamikeracel) for people with recessive dystrophic epidermolysis bullosa (RDEB). Developed by Abeona Therapeutics, Zevaskyn, formerly known as pz-cel or EB-101, was recently approved by the U.S. Food and Drug Administration (FDA) to treat RDEB wounds in adults and children. According to the c…

Lurie Children’s Becomes First Treatment Center for Zevaskyn Gene Therapy in Patients with RDEB

ZEVASKYN, the first FDA-approved gene therapy for wounds in recessive dystrophic epidermolysis bullosa, is now available at Lurie Children's Hospital.